Nuvation Bio Inc.
$5.85
-$0.22 (-3.62%)
$5.82Day Range$6.18
Key Statistics
Market Cap
$2.05B
Shares Outstanding
351.1M
Primary Exchange
XNYS
Currency
USD
Type
CS
IPO Date
Feb 10, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$6.15
Day High
$6.18
Day Low
$5.82
Volume
4.43M
VWAP
$5.92
Prev Close
$6.07
Transactions
--
Acc. Volume
--
About Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
PHARMACEUTICAL PREPARATIONSSIC 2834305 employees1500 BROADWAY, NEW YORK, NY, 10036332-208-6102IPO Feb 10, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001811063
- Composite FIGI
- BBG00VHJ0CC1
- Share Class FIGI
- BBG00VHJ0CD0
- Ticker Root
- NUVB
- SIC Code
- 2834
About Nuvation Bio Inc. (NUVB) Stock
Nuvation Bio Inc. (NUVB) closed the 2026-09-18 session at $5.85, down 3.62% versus the previous close (-0.22). The stock opened at $6.15 and traded between $5.82 and $6.18 during that session. Session trading volume was 4.4M shares. The volume-weighted average price (VWAP) is $5.92.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Nuvation Bio Inc. has a market capitalization of $2.05 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. NUVB is listed on the XNYS exchange. The company employs approximately 305 people. Nuvation Bio Inc. is headquartered in NEW YORK, NY. The recorded listing date is 2021-02-10.
On this page you can find market NUVB stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.